← 홈

방광·요로상피

85개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 85개
ADCBiologicstaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin Tislelizumab)

Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 17상태 ACTIVE
AntibodystaleAkesoPhase 2

Ivonescimab（AK112，a PD-1/VEGF bispecific antibody） (Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）)

Bladder Cancer; Muscle-invasive Bladder Cancer · PD-1

#PD-1#Antibody#Phase2#항체#면역항체+4
임상시험 16상태 RECRUITING
ADCBiologicstaleALX Oncology Inc.Phase 2

Evorpacept (Evorpacept)

Head and Neck Cancer; Head and Neck Squamous Cell Carcinoma · Bladder Cancer

#BladderCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 14상태 ACTIVE
ADCBiologicstaleArcus Biosciences, Inc.Phase 2

Quemliclustat (Quemliclustat)

Locally Advanced Bladder Urothelial Carcinoma; Locally Advanced Renal Pelvis Urothelial Carcinoma · Prostatic Neoplasms, Castration-Resistan

#ProstaticNeoplasmsCastration-Res#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 14상태 RECRUITING
ADCBiologicstaleVasgene Therapeutics, IncPhase 3

SEphB4-HSA (SEphB4-HSA)

Muscle-Invasive Bladder Carcinoma; Metastatic Urothelial Carcinoma · Muscle-Invasive Bladder Carcinoma

#Muscle-InvasiveBladderCarcinoma#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 5%임상시험 14상태 RECRUITING
ADCBiologicstaleRemeGen Co., Ltd.Phase 2

disitamab vedotin (Disitamab Vedotin, RC48, RC48-ADC and JS001)

Urothelial Carcinoma · Urothelial Carcinoma

#UrothelialCarcinoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 13상태 ACTIVE
AntibodystaleBeiGenePhase 2

disitamab vedotin (Disitamab Vedotin, RC48, RC48 Combined With Tislelizumab)

Upper Tract Urothelial Carcinoma · PD-1

#PD-1#Antibody#Phase2#항체#면역항체+3
임상시험 12상태 RECRUITING
ADCBiologicstalePfizerPhase 2

PF-08634404 (PF-08634404)

Urothelial Cancer; Advanced/Metastatic Urothelial Cancer · Urothelial Cancer

#UrothelialCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 11상태 RECRUITING
AntibodystaleMerckPhase 2

pembrolizumab (Keytruda, Coformulated favezelimab/pembrolizumab)

Metastatic Urothelial Carcinoma; Urothelial Neoplasms · Metastatic Urothelial Carcinoma

#MetastaticUrothelialCarcinoma#Antibody#Phase2#항체#면역항체+3
효능 ORR 6.8%임상시험 6상태 RECRUITING
ADCBiologicstaleRemeGenApproved

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin and Gemcitabine)

Radical Cystectomy; Urothelial Carcinoma · Radical Cystectomy

#RadicalCystectomy#ADC#Approved#항체약물접합체#antibody-drug-conjugate+2
임상시험 6상태 ACTIVE
AntibodystaleThe Affiliated Nanjing Drum Tow…Phase 2

Triplizumab (Triplizumab)

Bladder Cancer · Bladder Cancer

#BladderCancer#Antibody#Phase2#항체#면역항체+2
임상시험 6상태 ACTIVE
ADCBiologicstaleCSPC Megalith Biopharmaceutical…Phase 2

SYS6002 (SYS6002)

Advanced Urothelial Carcinoma · Advanced Urothelial Carcinoma

#AdvancedUrothelialCarcinoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 5상태 RECRUITING
ADCBiologicstaleMerck Sharp & Dohme LLCPhase 2

MK-3120 (MK-3120)

Bladder Cancer · Bladder Cancer

#BladderCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 4상태 RECRUITING
ADCBiologicstaleMedical Research CouncilPhase 1

Paclitaxel/Docetaxel/Ifosfamide (Paclitaxel/Docetaxel/Ifosfamide)

Muscle Invasive Bladder Urothelial Carcinoma · Muscle Invasive Bladder Urothelial Carci

#MuscleInvasiveBladderUrothelialC#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 0%임상시험 3상태 ACTIVE
AntibodystaleMerckPhase 2

pembrolizumab (Keytruda, Coformulated vibostolimab/pembrolizumab)

Metastatic Urothelial Carcinoma; Urothelial Neoplasms · Metastatic Urothelial Carcinoma

#MetastaticUrothelialCarcinoma#Antibody#Phase2#항체#면역항체+3
임상시험 2상태 RECRUITING
AntibodystaleMerck KGaAPhase 1

Methotrexate/Vinblastine/Doxorubicin/Cisplatin/Avelumab (Methotrexate/Vinblastine/Doxorubicin/Cisplatin/Avelumab)

Muscle Invasive Bladder Urothelial Carcinoma · Muscle Invasive Bladder Urothelial Carci

#MuscleInvasiveBladderUrothelialC#Antibody#Phase1#항체#면역항체+2
임상시험 2상태 ACTIVE
ADCBiologicstaleAstellas Pharma Global Developm…Phase 1

AGS15E (AGS15E)

Metastatic Urothelial Cancer · Metastatic Urothelial Cancer

#MetastaticUrothelialCancer#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 ACTIVE
AntibodystaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, AMVAC + Nivolumab)

Muscle-Invasive Bladder Carcinoma · Muscle-Invasive Bladder Carcinoma

#Muscle-InvasiveBladderCarcinoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
ADCBiologicstaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin and Toripalimab)

Muscle Invasive Bladder Cancer; HER2 Expression · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 1상태 ACTIVE
AntibodystaleAstraZenecaPhase 2

Cohort 1-3 (Durvalumab, Durvalumab (Cohort 1-3))

Urothelial Carcinoma; Bladder Cancer · Urothelial Carcinoma

#UrothelialCarcinoma#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING

3 / 5 페이지

← 이전다음 →